Navigation Links
ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
Date:3/29/2011

ufficient or inconclusive, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, or deny the approval of C1 esterase inhibitor for treatment of acute antibody-mediated rejection. These factors, and other factors, including, but not limited to those described in our annual report on Form 10-K for the year ended December 31, 2010 as filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
2. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
3. ViroPharma Announces Securities Repurchase Program
4. ViroPharma to Participate in Two March Healthcare Conferences
5. ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
6. ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
7. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
8. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
9. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
10. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
11. ViroPharma To Participate in Two September Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Semler Scientific, Inc. (Nasdaq: SMLR ... to healthcare insurers and physician groups, today reported financial ... "In the second quarter of 2015, ... growth of 54%, quarter over quarter revenue growth of ... base of FloChec® units of 18%," said Doug Murphy-Chutorian, ...
(Date:7/31/2015)... and SAN DIEGO , July ... parent company Eisai Co., Ltd. (Headquarters: Tokyo ... "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San ... Helen Torley , "NASDAQ: HALO") have signed a clinical ... Halaven ® , "eribulin") in combination with Halozyme,s investigational ...
(Date:7/31/2015)... 2015  Xencor, Inc. (NASDAQ: XNCR ), a ... treatment of autoimmune diseases, asthma and allergic diseases, and ... Hata to its board of directors. ... development is a tremendous asset to our board," said ... officer of Xencor. "Xencor faces a range of opportunities ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Pharmaceuticals, Inc. (NASDAQ: AUXL ), a specialty biopharmaceutical ... Monday, August 1, 2011 before the opening of the U.S. ... that day at 10:00 a.m. ET to discuss results and ... be used during the call will be available on the ...
... 18, 2011 Reportlinker.com announces that ... available in its catalogue: ... BRICS (Brazil, Russia, India, China, South ... http://www.reportlinker.com/p0573105/Neurosurgical-Products-Market-Outlook-in-BRICS-Brazil-Russia-India-China-South-Africa-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging Neurosurgical ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011 2Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011 3Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 2Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 3Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 4Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 5Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 6Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 7Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 8Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 9Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 10Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 11Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 12Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 13Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 14Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 15
(Date:7/31/2015)... , ... July 31, 2015 , ... Indosoft, Inc., is ... in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for ... agent script display logic shows the script components to the agent only when wanted, ...
(Date:7/31/2015)... ... ... a reputable source of authentic USA vs. Australia tickets at Ford Field in ... in conjunction with their Victory Tour to celebrate winning the 2015 Women's World Cup by ... awarded the Golden Ball as the best player of the 2015 Women's World Cup. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe , a ... redesigned website at Healthpointe.net. The new website will feature a sleek and streamlined ... serves to provide smoother interactions between patients and the Healthpointe clinics and ensures ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, ... LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper ... care providers understand the benefits of using medication management technologies . ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... According to ... as a direct result of heroin use and eventual overdoses. Thricefold deaths have held ... to get a handle on the Sarasota heroin epidemic, which was spurred by the ...
Breaking Medicine News(10 mins):Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:Healthpointe Announces Newly Redesigned Website 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3
... A twisted ankle or sudden palpitations while sightseeing around the ... stationed //in the complex of the 17th century monument to ... to a request by the Uttar Pradesh Tourism Development Corp ... complex., ,Medical facilities will also be made available in ...
... Family Welfare, has a contingency plan to manage ... active surveillance, preventive public health// measures, clinical management, ... IEC activities. ,This plan was operationalized ... in Nundurbar and Jalgaon districts of Maharashtra, Surat ...
... political leaders of the Western Pacific region to take action ... the phenomenal increase// in Aids infection with figures escalating to ... in the previous year. WHO has issued the call to ... spreading of the virus. ,Mr. Shigeru Omi, ...
... do, where an average man can talk around 7000 words per ... wonder it is// common to find many women complaining of the ... psychiatrist at University of California, author of a book called “The ... devote more brain cells in communicating that is why they tend ...
... The usage of condoms among the gay population will be promoted ... to be flagged off in the coming year. The program aims ... nation. ,The chief focus of the program will ... ensure that at least 70% of all gays use condoms at ...
... wines that belong to the vineyards of France and Italy are ... effects of fatty meals on the heart can be offset by ... has shown. Wines from these regions contain high levels of a ... have also proved the heart healthy benefits of a daily glass ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: